Spero Therapeutics Inc
NASDAQ:SPRO 4:00:00 PM EDT
| Market Cap (Intraday) | 79.19M |
| Current PE | 3.47 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.58 |
| 50-Day MA | $1.63 |
| 200-Day MA | $1.40 |
Spero Therapeutics Inc Stock, NASDAQ:SPRO
675 Massachusetts Avenue, 14th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.242.1600
Number of Employees: 46
Description
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.